Back to Search Start Over

Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

Authors :
Chu Lin
Xiaoling Cai
Wenjia Yang
Fang Lv
Lin Nie
Linong Ji
Source :
BMC Medicine, Vol 18, Iss 1, Pp 1-23 (2020)
Publication Year :
2020
Publisher :
BMC, 2020.

Abstract

Abstract Background The placebo response in patients with diabetes mellitus is very common. A systematic evaluation needs to be updated with the current evidence about the placebo response in diabetes mellitus and the associated factors in clinical trials of anti-diabetic medicine. Methods Literature research was conducted in Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for studies published between the date of inception and June 2019. Randomized placebo-controlled trials conducted in type 1and type 2 diabetes mellitus (T1DM/T2DM) were included. Random-effects model and meta-regression analysis were accordingly used. This meta-analysis was registered in PROSPERO as CRD42014009373. Results Significantly weight elevation (effect size (ES) = 0.33 kg, 95% CI, 0.03 to 0.61 kg) was observed in patients with placebo treatments in T1DM subgroup while significantly HbA1c reduction (ES = − 0.12%, 95% CI, − 0.16 to − 0.07%) and weight reduction (ES = − 0.40 kg, 95% CI, − 0.50 to − 0.29 kg) were observed in patients with placebo treatments in T2DM subgroup. Greater HbA1c reduction was observed in patients with injectable placebo treatments (ES = − 0.22%, 95% CI, − 0.32 to − 0.11%) versus oral types (ES = − 0.09%, 95% CI, − 0.14 to − 0.04%) in T2DM (P = 0.03). Older age (β = − 0.01, 95% CI, − 0.02 to − 0.01, P

Details

Language :
English
ISSN :
17417015
Volume :
18
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.60aeeafbb1145bdb65841aeccd2a405
Document Type :
article
Full Text :
https://doi.org/10.1186/s12916-020-01787-4